Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants

by Joseph Chen, Brett Houk, Yazdi K. Pithavala, Ana Ruiz‐Garcia
Published 2021-02-01

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

by Ana Ruiz-Garcia, Weiwei Tan, Jerry Li, May Haughey, Joanna Masters, Jennifer Hibma, Swan Lin
Published 2020-04-01

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

by Joseph Chen, May Haughey, Erik Vandendries, Daniel J. DeAngelo, Hagop M. Kantarjian, Ana Ruiz‐Garcia
Published 2021-01-01

Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome

by Rena Eudy‐Byrne, Nicole Zane, Susan C. Adeniyi‐Jones, Marc R. Gastonguay, Ana Ruiz‐Garcia, Gagan Kaushal, Walter K. Kraft
Published 2021-11-01

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

by Nadia Terranova, Jonathan French, Haiqing Dai, Matthew Wiens, Akash Khandelwal, Ana Ruiz‐Garcia, Juliane Manitz, Anja vonHeydebreck, Mary Ruisi, Kevin Chin, Pascal Girard, Karthik Venkatakrishnan
Published 2022-03-01